MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - September 21, 2012) - Today at 3:00 p.m.
CET (2:00 p.m. BST, 9:00 a.m. EDT), the Management Board of
MorphoSys AG will host a public conference call and webcast to present
information on the results of the clinical phase 1b/2a trial of MorphoSys's
proprietary antibody MOR103 in patients with rheumatoid arthritis, which
Dial-in numbers for the Conference Call (listen-only):
Germany: +49 (0) 89 2444 32975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation
a simultaneous slide presentation online at http://www.morphosys.com.
An audio replay and manuscripts of the conference will be
www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
on engineering the medicines of tomorrow. MorphoSys is listed on the
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
MOR103 is a fully human antibody against GM-CSF (granulocyte
stimulating factor). GM-CSF was originally identified as a growth factor
granulocytes and macrophages but has more recently been identified as an
inflammatory mediator in autoimmune disorders such as RA. GM-CSF stimulates
cells to produce granulocytes and other macrophages and subsequently
these differentiated immune cells leading to an increased production of
pro-inflammatory cytokines, chemokines and proteases and thereby ultimately
articular destruction. The antibody MOR103 blocks GM-CSF and reduces its
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Conference Call Alert:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE